PNC Financial Services Group Inc. Purchases 700 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)

PNC Financial Services Group Inc. lifted its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) by 8.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,200 shares of the company’s stock after purchasing an additional 700 shares during the period. PNC Financial Services Group Inc.’s holdings in MoonLake Immunotherapeutics were worth $359,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Deutsche Bank AG grew its position in MoonLake Immunotherapeutics by 59.8% during the fourth quarter. Deutsche Bank AG now owns 903 shares of the company’s stock worth $49,000 after buying an additional 338 shares in the last quarter. Geode Capital Management LLC grew its position in MoonLake Immunotherapeutics by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 58,950 shares of the company’s stock worth $3,192,000 after buying an additional 540 shares in the last quarter. US Bancorp DE grew its position in MoonLake Immunotherapeutics by 114.4% during the first quarter. US Bancorp DE now owns 2,208 shares of the company’s stock worth $86,000 after buying an additional 1,178 shares in the last quarter. LPL Financial LLC grew its position in MoonLake Immunotherapeutics by 19.5% during the fourth quarter. LPL Financial LLC now owns 8,146 shares of the company’s stock worth $441,000 after buying an additional 1,332 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in MoonLake Immunotherapeutics by 13.7% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,456 shares of the company’s stock worth $837,000 after buying an additional 1,866 shares in the last quarter. Institutional investors own 93.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on MLTX shares. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $67.00 target price on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 3rd. Wolfe Research raised MoonLake Immunotherapeutics from a “peer perform” rating to an “outperform” rating and set a $61.00 target price on the stock in a report on Monday, May 19th. Redburn Atlantic raised MoonLake Immunotherapeutics to a “hold” rating in a report on Monday, July 28th. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 target price on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $80.00 target price (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, MoonLake Immunotherapeutics has a consensus rating of “Moderate Buy” and an average target price of $74.43.

MoonLake Immunotherapeutics Trading Down 0.9%

NASDAQ MLTX opened at $54.39 on Friday. The company has a quick ratio of 16.65, a current ratio of 16.65 and a debt-to-equity ratio of 0.21. MoonLake Immunotherapeutics has a twelve month low of $31.42 and a twelve month high of $58.26. The company has a market cap of $3.48 billion, a price-to-earnings ratio of -19.56 and a beta of 1.27. The business’s fifty day moving average is $49.60 and its 200 day moving average is $43.46.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.14). During the same quarter in the prior year, the business earned ($0.39) earnings per share. As a group, sell-side analysts expect that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

MoonLake Immunotherapeutics Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.